XKRX
064550
Market cap105mUSD
Jul 10, Last price
6,410.00KRW
1D
3.89%
1Q
-38.60%
Jan 2017
-13.03%
IPO
-49.53%
Name
BioneerCorp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bioneer Corporation, established in 1992 and headquartered in Daejeon, South Korea, is a biotechnology company involved in diverse fields such as research products, molecular diagnostics, pharmaceuticals, and probiotics. For the biotechnology research market, Bioneer offers a wide array of consumables and reagents, including PCR and RT-PCR kits, real-time PCR solutions, RNA interference products, various chemicals, plastic laboratory essentials, and buffer solutions. The company also provides an extensive range of services like sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher services, electrophoresis, genome-wide functional analysis, and magnetic separation techniques. Additionally, Bioneer manufactures sophisticated instruments for conventional and real-time PCR, sample preparation, protein synthesis, centrifugation, vortex mixing, electrophoresis, spectrophotometry, and microbial culture. In molecular diagnostics, it supplies MDx technologies, human diagnostic kits, MDx extraction kits, and the necessary instrumentation. Furthermore, Bioneer develops specialized products for animal health and cutting-edge nano-biotechnology applications.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||